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Background. Bypass surgery has a failing frequency of 30% during the first year, mainly due to intimal hyperplasia (IH).
This negative effect is most pronounced in artificial grafts. Photodynamic therapy (PDT) is a technique in which light
activates photosensitizer dyes to produce free-radicals resulting in an eradication of cells in the vascular wall. The aim
of this study was to determine the effectiveness of PDT to reduce IH in a preclinical porcine PTFE bypass model.
Material and methods. Ten pigs were used. After a pilot PDT dosimetry study (n¼ 3) PTFE grafts were bilaterally
placed into the circulation as bypasses from the common to the external iliac arteries (n¼ 7). The right sides served as
controls (C). Before implantation of the left grafts, the arterial connecting sites of the left distal anastomoses were PDT-
treated. The arteries were pressurized at 180 mmHg for 5 minutes with the photosensitizer Methylene Blue (330 mg/ml),
and thereafter endoluminally irradiated with laser light (l¼ 660 nm, 100 mW/cm2, 150 J/cm2). After 4 weeks the speci-
mens were retrieved and formalin fixed. Cross sections through the midportions of the distal anastomoses and the grafts
were used for histology, immunohistochemistry to identify inflammatory cells and morphometric evaluation (n¼ 7).
Results. No systemic side effects and no graft occlusions were noted. PDT-treated anastomoses showed reduced IH in the
mid-portions of the anastomoses (Area of IH: mm2/mm graft: C: 6970 1536, PDT: 2734 2560; P< 0.005) as well as in
the grafts (C: 5391 4031, PDT: 777 1331; P< 0.02). The number of inflammatory cells per microscopic field was
increased after PDT (C: 24 16, PDT: 37 15; P< 0.009).
Conclusions. Adjuvant PDT, performed in an endovascular fashion, was a safe method to reduce prosthetic graftstenosis
in a preclinical setting. This study underscores the clinical potential of PDT to inhibit the development of clinical bypass
graftstenosis.
 2007 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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One of the major drawbacks to vascular bypass sur-
gery is the incidence of graft stenosis especially at
the site of the distal anastomosis, resulting, in part,
from intimal hyperplasia (IH). IH results from vessel
wall injury and involves the migration and prolifera-
tion of smooth muscle cells and myofibroblasts into
the subintimal space of the vessel with excessive de-
position of extracellular matrix proteins.1 Although
several attempts have been made, there is so far no
generally accepted treatment modality to clinically re-
duce the occurrence of graft stenosis. The major ap-
proaches used in the search for drugs to reduce
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agents and those that interfere with cell proliferation
and migration. However, only few of them have
shown promising results in randomized clinical
trials.2 Adjuvant radiotherapy and the implantation
of drug-eluting stents to reduce restenosis after angio-
plasty and in-stent restenosis especially in the coro-
nary system have been shown to reduce restenosis
in clinical trials, but have not been used at prosthetic
bypass anastomoses.3,4 The dominant focus of photo-
dynamic therapy (PDT) research has been on the
treatment of neoplasms. PDT has also gained interest
as a local vascular therapeutic approach to inhibit
IH.5e11 PDT is a photochemical process that uses light
at a specific wavelength to activate otherwise rela-
tively inert photosensitiser dyes for the production
of free-radical moieties.12 These reactive species exert
their cytotoxic effects by damaging cellular organelles
and membranes, but have also been found to affectlar Surgery. Published by Elsevier Ltd. All rights reserved.
334 J. Heckenkamp et al.extracellular matrix molecules.13 Since IH is an iatro-
genic, local obstruction, the precise and strictly local
cytotoxic effects of PDT seem to be very well suited
for endovascular therapy to inhibit the development
of graft stenosis. PDT treatment of balloon injured
carotid rat arteries reduces the amount of IH. With
correct dosimetry of PDT, acute depletion of endothe-
lial cells, medial smooth muscle cells, and adventitial
fibroblasts has been observed in the targeted segment.
This occurs without thrombus formation, develop-
ment of aneurysms, or inflammatory cell infiltra-
tion.14,15 Research in vascular PDT applications has
focused on the post-interventional arterial wound
healing. However, PDT also has shown promising
results to inhibit vein graft failure.16,17
The role of PDT to prevent prosthetic graft failure is
unknown. Since it is acknowledged, that intimal hy-
perplasia in prosthetic grafts is, in part, due to arterial
cell ingrowth.
It can be hypothesized that a PDT-induced elimina-
tion of that cell population may favourably modulate
the vascular wound healing response and therefore
improve the patency rate of these grafts. This study
was performed to investigate whether PDT has
a role in reducing intimal hyperplasia in prosthetic
grafts in a preclinical setting using a porcine iliac
PTFE bypass model.
Materials and Methods
Animal model
Ten male castrated domestic pigs, weighing approxi-
mately 25 kg were used in the study. Anaesthesia
was induced with intramuscular ketamine hydroclor-
ide (10 mg/kg) and thiopentalnatrium (10 mg/kg)
and maintained after endotracheal intubation with
isoflurane. Animal protocols were approved by the
ethical committee at Gothenburg University and con-
formed to guidelines set forth by national laws.
The used photosensitizer and laser-light dosimetry
was evaluated in a pilot study (3 pigs). Both iliac
arteries were used for PDT and the specimens were
harvested after 24 hours. PDT-treatment used fluence
of 100, 150 and 200 J/cm2, the photosensitizer Methy-
lene Blue was locally administered for 2 minutes at
concentrations of 250 and 330 mg/ml, based on a small
animal study.15 For the final study, a photosensitizer
dose of 330 mg/ml and a light dose of 150 J/cm2
were used, based on the histological findings of the
pilot study (Fig. 1).
PTFE-grafts (polytetrafluoroethylene), 5 mm inter-
nal diameter (FlowLine Bipore, Jotec GmbH, Germany),
Eur J Vasc Endovasc Surg Vol 34, September 2007were bilaterally placed into the circulation as bypasses
from the common to the external iliac arteries as
described before in 7 pigs.18 The geometry of the
anastomoses was designed uniformly in all animals.
Before graft-implantation the left arterial segment
for the future distal anastomosis was pressurized at
180 mmHg for 5 minutes with the photosensitizer
Methylene Blue (330 mg/ml) and endovascular PDT
application performed as described previously. The
control side was pressurized using saline solution.6
The segment was irradiated endoluminally with
homogenous laser light, emitted by a diode laser (B
and W Tek Inc., Newark, USA), to deliver 150 J/cm2
Fig. 1. Representative light micrographs of PDT-treated cross
sections using different doses. (330 mg/ml Methylene Blue;
a: 100 J/cm2, b: 150 J/cm2, c: 200 J/cm2). Specimens were
harvested 24 hours after PDT. Note the remaining cells
after PDT using 100 J/cm2, the few faint stained cells after
150 J/cm2 in the deeper layers of the media (b, see arrows)
and the polynuclear cells in the upper layers of the media
after 200 J/cm2 (c, see arrows).
335PDT Reduces IH in Prosthetic Vascular Bypassat an irradiance of 100 mW/cm2 at a wavelength of
660 nm. Homogenous intraluminal light emission
was achieved by coupling the laser to a 600 mm optical
fiber with a 3 cm diffuser tip, introduced into a trans-
parent balloon angioplasty catheter (Opta Pro,
Cordis, Germany, Fig. 2). Anastomoses were sutured
end to side using 6-0 polypropylene sutures (Ethicon,
Germany). The native iliac arteries were ligated to
shunt the blood flow through the implanted grafts.
Heparin was given intravenously (400 U/kg) before
clamping and an additional dose of 200 U/kg was
injected after two hours of surgery. Antibiotics were
administered intramusculary (dihydrostreptomycin
6.5 mg/kg and benzylpenicillin 5 mg/kg) for a total
of 3 days. After 4 weeks the animals were sacrificed
under general anaesthesia by a potassium chloride
overdose and the specimens were retrieved.
Tissue samples and histomorphometry
Both grafts were removed together with the native
vessels en bloc and flushed with isotonic saline solu-
tion. Specimens from the mid portion of the distal
anastomoses and the graft adjacent to these anasto-
moses were immersed in 4% formalin, buffered with
sodium phosphate, for approximately 12 hours. Dehy-
dration was performed in a graded series of ethanol
(70, 95, 99.5%), xylene, and finally the specimens
were embedded in paraffin.
The specimens were stained with hematoxylin and
eosin for descriptive histologic and morphometric
analyses. Areas of intimal hyperplasia were quanti-
fied at the midportion of the anastomoses and the
adjacent graft using light microscopy with Kontron
Electronic image analysing system (KS 400 version
2.0, Carl Zeiss, Germany).
Fig. 2. Intraoperative figure showing the inserted and in-
flated balloon angioplasty catheter with the optical fiber
emitting 660 nm monochromatic light. The left side of the
picture is showing the distal part of the vessel, the crossing
ureter is marked with an arrow.Immunohistochemistry
For antigen retrieval, sections were treated with pro-
teinase K (DAKO, Denmark) for 5 min. To block en-
dogenous peroxidase and non-specific binding sites,
the specimens were incubated for 5 min with 3%
hydrogen peroxide and 15 min with 5% milk powder
solution (Semper, Sweden). An anti-human monocyte/
macrophage antibody recognizing the intra-
cytoplasmatic antigen (L1 or Calprotectin) in mono-
cytes, tissue macrophages and granulocytes (1:100,
clone MAC 387, Serotec, England) was used. The
specimens were incubated with the primary antibody
for 3 h at room temperature and for 30 min with the
secondary antibody conjugated with horseradish
peroxidase (EnVision kit, DAKO). DAB substrate
(Vector Laboratories) was used for visualization. Nu-
clei were counterstained with hematoxylin. Control
slides with non-immune IgG as primary antibody
were included. A leukocyte count was performed in
the vessel wall of the recipient artery by counting
the positive cells at 4 different locations per specimen
(clock-wise at 12, 3, 6 and 9) using light microscopy
(400 magnification). The mean of the four values
was used as one data point.18
Statistical evaluation
All values are expressed as the mean SD. Differ-
ences in IH development and differences assessed
using paired t-test with a P< 0.05 being significant.
Results
Pilot study
No thrombosis was noted in any artery of the 3 pigs.
Using a photosensitizer concentration of 250 mg/ml,
complete cell eradication could not be achieved with
any of the light doses. Using a Methylene Blue at
330 mg/ml, different histological results were noted.
With a fluence of 100 J/cm2 a significant cell numbers
were still present in the media (Fig. 1a). At 150 J/cm2
almost all medial cells were absent, with the exception
of some faintly staining cells in the deeper layers of
the media (Fig. 1b). At 200 J/cm2 some inflammatory
appearing cells were noted in the luminal medial
layers (Fig. 1c). Therefore, the dose of 150 J/cm2 was
selected for the following experiments.
PDT bypass study
At the time of harvest, all animals appeared healthy
and had no evidence of weight loss or wound
Eur J Vasc Endovasc Surg Vol 34, September 2007
336 J. Heckenkamp et al.infection. No bypass occlusion was observed in the
time frame of 4 weeks.
At the distal anastomosis the area of IH (mm2/mm
graft) in controls was 6970 1536 whereas the area
of IH after PDT was 2734 2560 (P< 0.005, Fig. 3).
No gross thrombus was noted. The media consisted
of normal appearing matrix tissue in both groups,
but cellularity appeared to be reduced after PDT.
The adventitia of both groups comprised loose con-
nective tissue interspersed with fibroblast-like cells
(Fig. 4).
In the bypass graft the area of IH (mm2/mm length)
in controls was 5391 4031, whereas the area of IH af-
ter PDT of the artery on the PDT-treated side was
777 1331 (P< 0.02, Fig. 5). The lesions in controls
appeared typical of IH, with mesenchymal cells
embedded in extracellular matrix (Fig. 6).
The number of inflammatory cells (cells per micro-
scopic field 400) in controls was 24 16 whereas the
number of inflammatory cells after PDT was 37 15
(P< 0.009, Fig. 7).
Discussion
The occurrence of anastomotic and graft intimal hy-
perplasia with subsequent graft failure in peripheral
PTFE bypass graft surgery remains an unsolved prob-
lem. For the first time we have demonstrated, in a por-
cine model, that the adjuvant application of arterial
PDT at the site of the distal anastomosis can reduce
the amount of intimal hyperplasia at the anastomosis
and within the graft.
The mechanisms of vascular PDT to reduce re-
stenosis in the arterial system after vascular
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Fig. 3. Area of intimal hyperplasia at the midportion of the
anastomoses in control and PDT-treated specimens. The
area is calculated as mm2 intimal hyperplasia/mm graft.
Data are expressed as mean SD. P< 0.005 in controls vs.
PDT. N¼ 7 in both groups.
Eur J Vasc Endovasc Surg Vol 34, September 2007Fig. 4. Representative light micrograph of a PDT-treated (a)
and control (b) cross section of the distal anastomosis
stained with hematoxylin and eosin 4 weeks after surgery.
Note the elevated amount of intimal hyperplasia in the
control anastomosis compared to the PDT-treated anasto-
mosis (see arrows).
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Fig. 5. Area of intimal hyperplasia in bypass grafts of un-
treated and PDT-treated specimens. Area is calculated as
mm2 intimal hyperplasia/mm graft. Data are expressed as
mean SD. P< 0.02 in controls vs. PDT. N¼ 7 in both
groups.
337PDT Reduces IH in Prosthetic Vascular Bypassinterventions have been investigated intensively in
small animal models.8,15,19,20 PDT has also been ap-
plied to large animal models and in human clinical
trials to investigate the role of PDT to inhibit resteno-
sis after balloon angioplasty.5,11,21 These studies have
demonstrated the safety and feasibility of vascular
PDT in humans.
Fig. 6. Representative light micrograph of a PDT-treated (a)
and control (b) cross section of the distal bypass graft
stained with hematoxylin and eosin 4 weeks after surgery.
Note the elevated amount of intimal hyperplasia in the con-
trol grafts compared to the PDT-treated grafts (see arrows).The established preclinical porcine model was well
suited for this study because it closely mimics human
healing in bypass grafts.18 As in humans, artificial vas-
cular grafts implanted into pigs do not seem to form an
endothelial lining. This is different to other experimen-
tal models, which in contrast to humans show artificial
graft healing with an endothelial coverage.22,23 Since
the distal anastomosis is the clinically relevant anasto-
mosis for graft failure in most cases,24 only this anasto-
mosis was PDT-treated and investigated in this study,
with local application of the clinically available photo-
sensitizer Methylene Blue. Despite the selectivity of
confined light irradiation after systemic photosensi-
tizer application, the site-specific delivery of a photo-
sensitizer has conceptual appeal. First, it would
achieve specific local drug concentrations. Second,
concentrating the drug at the target site could mini-
mize systemic adverse effects. All anastomoses were
performed uniformly, since the geometry of the anasto-
moses influences biomechanical variables, which are
important in the development of IH.25
Cells from the connected artery are considered to
be the major source of graft IH. Four weeks after sur-
gery, control grafts developed a considerable amount
of IH at the site of the distal anastomosis as well as in
the graft. In this time frame, IH did not cause graft
failure. However a further progression of IH in this
model might be expected, based on previous long-
term studies.18 In the present study PDT treatment
significantly reduced but did not eliminate IH, as
seen in small animal models. Perhaps, achieving cor-
rect photosensitizer and light and dosimetry in ar-
teries of bigger size is more difficult, compared to
smaller vessels. In small animal models, 24 hours after
PDT the arteries were found to be acellular.26 In the
pilot study using the porcine iliac artery model,
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Fig. 7. Inflammatory cells per microscopic field (400) in
untreated and PDT-treated specimens. Data are expressed
as mean SD. P< 0.009 in controls vs. PDT. N¼ 7 in both
groups.
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338 J. Heckenkamp et al.some remaining smooth muscle cells were noted in
the deeper layers of the media 24 hours after PDT.
This may be a result of suboptimal dosimetry or in-
complete dead cell removal from the artery within
this time frame of 24 hours due to the thickness of
the vessel. Dosimetry for the final study was not in-
creased further because of the inflammatory cells in
upper medial layers in the pilot study (Fig. 3c) and
it has been shown in small animals that a PDT over-
dose can also lead to photothrombosis of the vessel.27
These observations suggest that besides induction of
cytotoxicity, a dose-dependant alteration of the extra-
cellular environment also occurs. PDT has a small
therapeutic window, which needs to be addressed in-
tensively in human size arteries to avoid a too low
PDT dose with subsequent development of IH and
also to avoid too high doses with subsequent inflam-
matory cell attraction or thrombosis. In addition to
dosimetry issues, it has been shown that not only ar-
terial cells but also perivascular tissue cells and blood
cells might contribute to IH in this model.18 These
sources were not affected by PDT to the artery.
Further research is necessary to optimize PDT to re-
duce prosthetic bypass graft failure and elucidate the
mechanisms of reduced IH in this model. Our prom-
ising findings of the efficacy of PDT at reducing IH
in prosthetic grafts are limited to a time frame of 4
weeks. Long-term observations and optimized photo-
sensitizer and light dosimetry are necessary before
possible application to man.
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